PathAI, Maker of AI-enabled pathology products, announced a partnership with pharmaceutical and diagnostics giant Roche on Friday.
The strategic partnership enables PathAI to develop and distribute its AI pathology technology through Roches uPath business software, a workflow platform for laboratories.
The collaboration begins with the dissemination of PathAI’s research-only algorithms through the cloud version of Roche’s uPath software, with a focus on immuno-oncology for the treatment of various cancers.
WHY IT IS IMPORTANT
PathAI proposes the partnership to advance the adoption of AI-powered digital pathology technology in laboratories, which it believes has been slow as the digital pathology industry is fragmented among various software, hardware and algorithm vendors.
“This collaboration brings together all of the components required to deliver and market a differentiated AI-based medical device for digital pathology, including an assay, scanner, image management system and image analysis algorithms. We believe this collaboration will unlock the potential for digital pathology in the CDx [companion diagnostic] and offers biopharma sponsors a differentiated service and ultimately new opportunities to improve patient outcomes, “said Dr. Andy Beck, CEO of PathAI, in a statement.
THE BIGGER TREND
In July, PathAI added laboratory testing services to its portfolio the takeover of Poplar Healthcare Management.
The deal came months after the company announced it raised $ 165 million in Series C funding, bringing the total to $ 255 million.
In the meantime, Roche closed additional deals this year, including one with the pharmaceutical giant Eli Lilly for integration with his Tempo Pen and Tempo Smart Button. It also works with Diabeloop for automated insulin delivery and Novo Nordisk for integration with its diabetes management app mySugr.
Other companies in the digital pathology field are Proscia, which will be launched in March Partnership with the AI oncology diagnostic platform Ibex Medical Analytics; Paige, who received de novo clearance from the Food and Drug Administration last month for its prostate cancer detection AI software; and health technology giant Royal Philips, which today announced a new digital pathology suite called IntelliSite.